MAP2K7 and retinal vein occlusion: Ocular toxicity is also seen with MEK inhibitors, with retinal vein occlusion observed in 6% of patients treated with cobimetinib, resulting in permanent treatment discontinuation,10 while there was no relevant event occurrence that warranted attention with luvometinib in this study.